Delivery Order SPE2DB22D1202-SPE2DB25FVGE3
- Not listed
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Telmisartan-Amlodipine 40-5 mg tablets in a 30-count package. This competitively awarded, firm fixed-price delivery order has a ceiling value of $3,017.64 and is scheduled for completion by August 13, 2025. The contract is unsolicited for set-aside programs and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Telmisartan-Amlodipine 40-5 mg tablets (30-count supply) with a ceiling value of $1,939.39. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, completed on August 27, 2025. The pharmaceutical products will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $4,639.13 to AmerisourceBergen Drug Corp for Telmisartan-Amlodipine 40-5 mg tablets (30-count supply) on August 27, 2025, with a completion date of August 28, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a single shipment of a combination antihypertensive medication to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,108.69 to AmerisourceBergen Drug Corp for the supply of Telmisartan-Amlodipine 40-10mg tablets (30-count) with a completion deadline of September 15, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, placed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Telmisartan-Amlodipine 40-5 mg tablets (30-count) on August 12, 2025, with a ceiling value of $1,344.82 and ultimate completion date of August 13, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and running through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for telmisartan-amlodipine 40-10mg tablets (30-count supply) valued at $3,501.35 under a firm fixed price contract. The award was made on September 2, 2025, with an ultimate completion date of September 3, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded without any set-aside designation. This award represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Telmisartan-Amlodipine 40-5 mg tablets (30-count supply) on March 5, 2025, with a ceiling value of $2,115.16. This non-competitive, firm fixed price delivery order is set to be completed by March 6, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply needs. This delivery order falls...
- The Defense Logistics Agency awarded a $3,157.92 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30-count). This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The order falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Telmisartan-Amlodipine 80-10 mg tablets in a 30-count package. This $1,344.96 firm fixed price delivery order, without set-aside designation, is scheduled for completion by June 2, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award represents a pediatric/adult combination antihypertensive pharmaceutical product delivery to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,403.28 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Telmisartan-Amlodipine 80-5 mg tablets (30-count package). This firm fixed-price delivery order, with an ultimate completion date of September 2, 2025, represents a competitively awarded procurement with no set-aside designation. The contractor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVGE3Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Telmisartan-Amlodipine 40-5 mg tablets (30-count) with a ceiling value of $1,234.32 and an ultimate completion date of August 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls within AmerisourceBergen's comprehensive pharmaceutical supply agreement with the Defense Logistics Agency, which supports military healthcare systems and federal medical procurement needs globally. As a major pharmaceutical distributor, AmerisourceBergen supplies brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The Telmisartan-Amlodipine combination medication is a cardiovascular therapeutic used for hypertension management, consistent with the company's established portfolio of delivering critical pharmaceutical commodities to support military medical operations and veteran healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 8/1/25 |